MeiraGTx
New York · Founded 2015
About MeiraGTx
MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders. The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarily revolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $162.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2024)
- Ticker: nasdaq:MGTX
- Website: meiragtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/meiragtx-43388 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.